Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04606771 · ClinicalTrials.gov registry record · Phase 2

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
30
Enrollment target
20
Study locations

NCT04606771 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 30 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04606771, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
20
Study locations

Study Summary

This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Osimertinib + Savolitinib
  • DRUG Savolitinib + Placebo

Study Locations (20)

Other

  • Research Site - Ciudad de Buenos Aires
  • Research Site - Delhi
  • Research Site - Mumbai
  • Research Site - Taichung
  • Research Site - Taipei
  • Research Site - Taipei
  • Research Site - Taipei
  • Research Site - Taoyuan
  • Research Site - Bangkok
  • Research Site - Bangkok
  • Research Site - Bangkok
  • Research Site - Bangkok
  • Research Site - Bangkok
  • Research Site - Hat Yai
  • Research Site - Khon Kaen
  • Research Site - Muang
  • Research Site - Hanoi
  • Research Site - Hà Nội

California

  • Research Site - Duarte
  • Research Site - Sacramento

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-09-28
Est. Completion 2026-03-30
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04606771

The ClinicalTrials.gov registry entry for NCT04606771 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib + Savolitinib is the first listed.

NCT04606771 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, California.

Frequently Asked Questions

What is clinical trial NCT04606771 about?

NCT04606771 is a clinical study titled "A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC". This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer w...

What is the current status of trial NCT04606771?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-09-28. Estimated completion is 2026-03-30.

What conditions does trial NCT04606771 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT04606771?

The interventions under investigation include: Osimertinib + Savolitinib (DRUG), Savolitinib + Placebo (DRUG).

Who is sponsoring clinical trial NCT04606771?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04606771 being conducted?

This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.